Sana Biotechnology, Inc. (SANA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of SANA were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Sana Biotechnology
From the latest filingsOverall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SANA
210 funds and institutions reported SANA shares worth $649M at the end of Q2 2026, about 67% of the company. The largest holder is FMR LLC (Fidelity) with 13.4%.
Funds and institutions (13F) 67%Everyone else 33%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 37.43M | 13.45% | $131M | No change |
| Flagship Pioneering, LLC | 25.00M | 8.98% | $87.3M | No change |
| Ra Capital Management, L.P. | 18.75M | 6.74% | $65.4M | – |
| BlackRock, Inc. | 16.68M | 5.99% | $58.2M | +17% |
| State Street Corp | 11.20M | 4.03% | $39.1M | +6% |
| Canada Pension Plan Investment Board | 10.22M | 3.67% | $35.7M | No change |
| Vanguard Capital Management LLC | 8.38M | 3.01% | $29.2M | +13% |
| Bank of America Corp | 5.75M | 2.07% | $20.1M | +95% |
| Geode Capital Management, LLC | 4.68M | 1.68% | $16.3M | +12% |
| Marex Group Ltd | 3.99M | 1.43% | $13.9M | -0% |
| Marshall Wace, LLP | 2.93M | 1.05% | $10.2M | +341% |
| Alphabet Inc. | 2.81M | 1.01% | $9.8M | No change |
| Goldman Sachs Group Inc | 2.37M | 0.85% | $8.3M | -26% |
| Integral Health Asset Management, LLC | 2.00M | 0.72% | $7M | -38% |
| Toronto Dominion Bank | 1.97M | 0.71% | $6.9M | – |
| Vanguard Portfolio Management LLC | 1.88M | 0.68% | $6.6M | +10% |
| Jacobs Levy Equity Management, Inc | 1.87M | 0.67% | $6.5M | – |
| Northern Trust Corp | 1.60M | 0.58% | $5.6M | +8% |
| Charles Schwab Investment Management Inc | 1.38M | 0.50% | $4.8M | +1% |
| Sixth Street Partners Management Company, L.P. | 1.38M | 0.50% | $4.8M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No SANA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SANA short interest
High short interest. 13.5% of SANA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 40.60M SANA shares were sold short, 13.5% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 15.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 40.60M | 13.55% | -1% | 2.57M | 15.8 |
| Oct 15, 2026 | 40.85M | 13.64% | +5% | 3.72M | 11.0 |
| Sep 30, 2026 | 38.73M | 12.94% | -6% | 4.32M | 9.0 |
| Sep 15, 2026 | 41.37M | 13.82% | -0% | 3.39M | 12.2 |
| Aug 31, 2026 | 41.56M | 13.88% | -2% | 2.58M | 16.1 |
| Aug 14, 2026 | 42.57M | 14.22% | +1% | 2.37M | 18.0 |
| Jul 31, 2026 | 42.15M | 15.15% | +6% | 2.58M | 16.3 |
| Jul 15, 2026 | 39.74M | 14.28% | +3% | 3.01M | 13.2 |
| Jun 30, 2026 | 38.70M | 13.91% | -5% | 4.24M | 9.1 |
| Jun 15, 2026 | 40.67M | 14.62% | +3% | 3.68M | 11.1 |
| May 29, 2026 | 39.33M | 14.13% | +2% | 3.79M | 10.4 |
| May 15, 2026 | 38.47M | 13.82% | -6% | 4.51M | 8.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Sana Biotechnology company events
Sana Biotechnology filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 8, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 15, 2026AnnouncementSana Biotechnology, Inc. announced that it had sold an aggregate of 21,607,878 shares of its common stock, for aggregate net proceeds of approximately $69.0 million, pursuant to its amended and restated sales agreement with TD Securities (USA) LLC, acting as sales agent. 1 SIGNATURES Pursuant to… Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 24, 2026LeadershipIn order to achieve a more equal balance of director membership among the three classes of the Board of Directors of Sana Biotechnology, Inc. in accordance with the Company’s Amended and Restated Certificate of Incorporation, the Board determined that one of its Class I directors (with a term… Filing
- Apr 13, 2026AnnouncementSana Biotechnology, Inc. entered into a stock purchase agreement with Mayo Clinic, pursuant to which the Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares of the Company’s common stock, $0.0001 par value per share, at a price of $3.33… Filing
- Mar 3, 2026AnnouncementThe Company entered into an amended and restated sales agreement with TD Securities (USA) LLC to sell shares of the Company’s common stock, $0.0001 par value per share, from time to time, through an “at the market offering” program under which TD Cowen will act as sales agent. Filing
- Feb 17, 2026LeadershipSana Biotechnology, Inc. announced that Brian Piper, M.B.A., joined the Company as Executive Vice President, Chief Financial Officer on February 17, 2026, and in such capacity, will serve as the Company’s Treasurer and Principal Financial Officer. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sana Biotechnology financials
Famous investors that hold SANA
5 of the 50 well-known investors we track reported holding SANA in their latest 13F filing. The largest position is Jim Simons's, worth $4.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.42M | $4.1M | 0.0% | +15% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.20M | $3.5M | 0.0% | +642% |
| Israel Englander · Millennium Management | Q3 2026 | 389,728 | $1.1M | 0.0% | -40% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 252,908 | $737K | 0.0% | -58% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 149,679 | $436K | 0.0% | +70% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SANA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 12.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 12.5% |
Questions about Sana Biotechnology, Inc. (SANA) stock
Who owns the most SANA stock?
The largest reported owner of Sana Biotechnology, Inc. (SANA) is FMR LLC (Fidelity), with 13.4% of the company. In total, 210 funds and institutions reported holding SANA at the end of Q2 2026, together about 67% of the shares. See the largest owners.
Are SANA insiders buying or selling?
No SANA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in SANA?
As of Oct 30, 2026, 40.60M SANA shares were sold short, 13.5% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 15.8 trading days (days to cover). See the history.
Which famous investors hold SANA?
5 of the 50 well-known investors we track reported SANA in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $4.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.